As of November 6, 2026, Biodesix Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 5, 2026 (Form 8-K, November 5, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Biodesix Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Biodesix Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-05. Every row below is cited to the filing it comes from, and this page adds each new change as Biodesix Inc files it.
Also on the record for Biodesix Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 18, 2026 | Stake report, Schedule 13G, by Soleus Capital Master Fund, L.P. | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 4.6% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 4.1% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Orin Hirschman | 7.7% of the class | 5%+ stakes | Source |
| January 27, 2026 | Stake report, Schedule 13D/A, by SCHULER JACK W | 24% of the class | 5%+ stakes | Source |
| January 26, 2026 | Stake report, Schedule 13G, by Telemark Asset Management, LLC | 5.4% of the class | 5%+ stakes | Source |
| January 23, 2026 | Stake report, Schedule 13G/A, by Telemark Asset Management, LLC | 4.1% of the class | 5%+ stakes | Source |
| January 13, 2026 | Stake report, Schedule 13G, by Soleus Capital Master Fund, L.P. | 6.3% of the class | 5%+ stakes | Source |
| September 23, 2025 | Stake report, Schedule 13D/A, by SCHULER JACK W | 27% of the class | 5%+ stakes | Source |
| September 3, 2025 | Stake report, Schedule 13D/A, by SCHULER JACK W | 26% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Biodesix Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Biodesix Inc and the records around it.
Biodesix Inc elsewhere on the record
- 5%+ stake filings Jun 2026
- Who owns it
Companies that share a holder
- SCHULER JACK W also filed stake reports on 1 other company: Aspira Women's Health Inc. (Jun 2026)
- Telemark Asset Management, LLC also filed stake reports on 2 other companies: Andersen Group Inc. (Aug 2026), CODEXIS, INC. (Jul 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Watch Biodesix Inc
Get an email when Biodesix Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biodesix Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Biodesix Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biodesix Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-05 | Reported | not named in the filing | 8-K, 2026-11-05 |
New leaders reset buying decisions — get the Full Report on Biodesix Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Biodesix Inc, with the record behind each one.
Find candidates like senior executive at Biodesix IncEvery change, in the filing's words
Reported
On November 2, 2026, it was agreed that the employment of Kieran O'Kane, Chief Commercial Officer of Biodesix, Inc. (the "Company") would end effective November 2, 2026 (the "Separation Date").
- Mr. O'Kane will be eligible for separation benefits under his existing Executive Severance and Change in Control Agreement (the "Executive Agreement"), as described in the Company's 2026 Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 9, 2026, based on his qualifying termination of employment under the terms of the Executive Agreement.
Tools for this story
Each opens in a new tab, filled in for Biodesix Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.